Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 6/20 | 0.62 |
| ▸ | CTSL | P07711 | 6/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504338 | 1.00 | CTSV (0.62) | CTSVCTSLSIRT2HCAR2CHRM4 | |
| SCHEMBL33372525 | 0.91 | CTSV (0.51) | CTSVCTSLSIRT2MAOBKMT2A | |
| SCHEMBL21617191 | 0.91 | CTSV (0.51) | CTSVCTSLSIRT2MAOBKMT2A | |
| SCHEMBL8390211 | 0.82 | CTSV (0.66) | CTSVCTSLSIRT2HCAR2CHRM4 | |
| SCHEMBL21617165 | 0.81 | MAOB (0.46) | CTSVCTSLCHRM4MAOBMEN1 | |
| SCHEMBL31504355 | 0.81 | MAOB (0.46) | CTSVCTSLCHRM4MAOBMEN1 | |
| SCHEMBL8391099 | 0.78 | AKR1C3 (0.71) | CTSVCTSLSIRT2AKR1C3AKR1C2 | |
| SCHEMBL10833797 | 0.77 | SIRT2 (0.80) | CTSVCTSLSIRT2CHRM4CHRM3 | |
| SCHEMBL10983488 | 0.77 | CTSV (1.00) | CTSVCTSLSIRT2MEN1KMT2A | |
| SCHEMBL4251052 | 0.77 | TAS2R14 (0.61) | CLCN2AKR1C3AKR1C2CDC25BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820850-B1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-09-23 | — | — | US | disclosed |
| EP-3820850-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| CN-112638877-A | phenyl/pyridyl-N-phenyl/pyridyl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | NSUN3, CBR3, C1R | CTSV 1470/4885CTSL 3640/4885SIRT2 2763/4885 |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | NSUN3, CBR3, C1R | CTSV 1470/4885CTSL 3640/4885SIRT2 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.